Otsuka extends Penwest collaboration
This article was originally published in Scrip
Japan's Otsuka Pharmaceuticalhas extended its alliance with Penwest Pharmaceuticals to include a second unidentified compound, to which Penwest will apply its proprietary TIMERx formulation technology. The oral controlled-release delivery system is applicable to a range of products and allows less frequent dosing. The US firm will receive undisclosed fees and other payments as part of the agreement, which it will use to support the development of its in-house pipeline.